We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Analytical Cannabis Logo
Home > Resources > Videos > Content Piece

Standardizing Cannabis Products Could Redefine Medicine in the US

Published: Nov 02, 2018   

Dr Jahan Marcu, Chief Scientific Officer and Chief Auditor Americans for Safe Access and the Patient Focused Certification Program speaking at The Science of Cannabis 2017 Virtual Event. 

There needs to be standards, regulations, and traceability in the cannabis industry. Such responsibility is already deeply imprinted in the botanical medicine and herbal product industries; Good Manufacturing Practices (or any GxP) are the same across the industry and jurisdictional boundaries. At the state level, there has been a proliferation of policies and laws that relax cannabidiol issues, while operators and producers are voluntarily adopting good practices. However, a national policy must be adopted or the states will take on the responsibility of regulating cannabidiol across the country. For example, at least 20 state-based programs have adopted nearly identical regulatory requirements for medical cannabis products, these regulations were derived from best practices, developed through a voluntary consensus process, which took years to complete. As these policies are promulgated, insurance companies will be more involved, offering product liability insurance, ensuring effective recall programs and accountability.


Stay connected with the latest news in cannabis extraction, science and testing

Get the latest news with the FREE weekly Analytical Cannabis newsletter